Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CryoPort, Inc. stock logo
CYRX
CryoPort
$14.62
+1.7%
$12.42
$6.16
$16.73
$724.78M1.9991,421 shs502,102 shs
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
$15.34
-4.6%
$20.98
$6.57
$28.00
$793.71M1.441.07 million shs1.05 million shs
Replimune Group, Inc. stock logo
REPL
Replimune Group
$8.88
+3.0%
$5.25
$1.50
$13.24
$711.78M0.916.86 million shs1.97 million shs
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
$7.25
-5.7%
$7.40
$3.71
$8.74
$210.65M1.73776,372 shs943,384 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CryoPort, Inc. stock logo
CYRX
CryoPort
-2.64%-11.01%+10.28%+83.89%+108.10%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
+5.37%-9.36%-36.27%+15.52%+128.73%
Replimune Group, Inc. stock logo
REPL
Replimune Group
+1.77%-12.66%+110.76%+20.73%-11.86%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
0.00%+3.50%-5.88%+12.59%+22.08%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CryoPort, Inc. stock logo
CYRX
CryoPort
$14.62
+1.7%
$12.42
$6.16
$16.73
$724.78M1.9991,421 shs502,102 shs
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
$15.34
-4.6%
$20.98
$6.57
$28.00
$793.71M1.441.07 million shs1.05 million shs
Replimune Group, Inc. stock logo
REPL
Replimune Group
$8.88
+3.0%
$5.25
$1.50
$13.24
$711.78M0.916.86 million shs1.97 million shs
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
$7.25
-5.7%
$7.40
$3.71
$8.74
$210.65M1.73776,372 shs943,384 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CryoPort, Inc. stock logo
CYRX
CryoPort
-2.64%-11.01%+10.28%+83.89%+108.10%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
+5.37%-9.36%-36.27%+15.52%+128.73%
Replimune Group, Inc. stock logo
REPL
Replimune Group
+1.77%-12.66%+110.76%+20.73%-11.86%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
0.00%+3.50%-5.88%+12.59%+22.08%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CryoPort, Inc. stock logo
CYRX
CryoPort
2.80
Moderate Buy$15.113.36% Upside
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
2.89
Moderate Buy$47.43209.18% Upside
Replimune Group, Inc. stock logo
REPL
Replimune Group
1.70
Reduce$4.88-45.10% Downside
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
2.67
Moderate Buy$24.75241.38% Upside

Current Analyst Ratings Breakdown

Latest UNCY, CYRX, REPL, and JBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/9/2026
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
UpgradeSell (E+)Sell (D-)
6/8/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Set Price Target$13.50
6/8/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Reiterated RatingHold$13.00
6/3/2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
DowngradeSell (D-)Sell (E+)
6/3/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Boost Price TargetBuy$15.00 ➝ $20.00
6/2/2026
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
Reiterated RatingSpeculative Buy$15.00 ➝ $18.00
6/2/2026
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
Set Price Target$55.00
6/2/2026
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
Reiterated RatingBuy$47.00
6/2/2026
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
Boost Price TargetOutperform$34.00 ➝ $45.00
6/1/2026
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
Reiterated RatingBuy
6/1/2026
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
UpgradeSell (D-)Sell (D)
(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CryoPort, Inc. stock logo
CYRX
CryoPort
$176.18M4.18N/AN/A$9.19 per share1.59
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/AN/AN/AN/A$6.74 per shareN/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
N/AN/AN/AN/A$5.40 per shareN/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
$680K292.03N/AN/A$1.41 per share5.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CryoPort, Inc. stock logo
CYRX
CryoPort
$78.30M$1.3510.83N/AN/A41.57%-7.92%-4.79%8/4/2026 (Estimated)
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
-$127.41M-$2.02N/AN/AN/AN/A-51.34%-47.32%N/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
-$247.30M-$3.44N/AN/AN/AN/A-102.69%-72.22%6/12/2026 (Estimated)
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-$26.56M-$2.21N/A0.89N/AN/A-134.69%-84.51%8/13/2026 (Estimated)

Latest UNCY, CYRX, REPL, and JBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/12/2026Q4 2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
-$0.73N/AN/AN/A$5.57 millionN/A
5/12/2026Q1 2026
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-$0.4589-$0.54-$0.0811-$0.54$11.11 millionN/A
5/7/2026Q1 2026
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
-$0.52-$0.57-$0.05-$0.57N/AN/A
5/4/2026Q1 2026
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20-$0.23-$0.03-$0.25$44.86 million$47.80 million
3/30/2026Q4 2025
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-$0.46-$0.82-$0.36-$0.82$0.52 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/AN/AN/AN/AN/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
N/AN/AN/AN/AN/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CryoPort, Inc. stock logo
CYRX
CryoPort
N/A
2.09
2.00
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/A
14.29
14.29
Replimune Group, Inc. stock logo
REPL
Replimune Group
0.33
5.60
5.60
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
N/A
2.40
2.40

Institutional Ownership

CompanyInstitutional Ownership
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
92.53%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
40.42%

Insider Ownership

CompanyInsider Ownership
CryoPort, Inc. stock logo
CYRX
CryoPort
10.00%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
23.06%
Replimune Group, Inc. stock logo
REPL
Replimune Group
5.20%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
10.71%
CompanyEmployeesShares OutstandingFree FloatOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.40 million45.36 millionOptionable
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
2049.36 million37.98 millionN/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
21082.57 million78.28 millionOptionable
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
927.39 million24.46 millionNot Optionable

Recent News About These Companies

Unicycive Therapeutics Inc Ordinary Shares UNCY
Unicycive Therapeutics Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
CryoPort stock logo

CryoPort NASDAQ:CYRX

$14.62 +0.24 (+1.67%)
Closing price 04:00 PM Eastern
Extended Trading
$14.79 +0.17 (+1.16%)
As of 06:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Jade Biosciences stock logo

Jade Biosciences NASDAQ:JBIO

$15.34 -0.74 (-4.60%)
Closing price 04:00 PM Eastern
Extended Trading
$15.32 -0.03 (-0.16%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Replimune Group stock logo

Replimune Group NASDAQ:REPL

$8.88 +0.26 (+3.02%)
Closing price 04:00 PM Eastern
Extended Trading
$8.85 -0.04 (-0.39%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Unicycive Therapeutics stock logo

Unicycive Therapeutics NASDAQ:UNCY

$7.25 -0.44 (-5.72%)
Closing price 04:00 PM Eastern
Extended Trading
$7.33 +0.08 (+1.05%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.